In this review, we elucidate the mechanisms of Aβ oligomer toxicity which may contribute to Alzheimer’s disease (AD). In particular, we discuss on the interaction of Aβ oligomers with the membrane through the process of adsorption and insertion. Such interaction gives rises to phase transitions？in the sub-structures of the Aβ peptide from α-helical to β-sheet structure. By means of a coarse-grained model, we exhibit the tendency of β-sheet structures to aggregate, thus providing further insights to the process of membrane induced aggregation. We show that the aggregated oligomer causes membrane invagination, which is a precursor to the formation of pore structures and ion channels. Other pathological progressions to AD due to Aβ oligomers？are also covered,？such as their interaction with the membrane receptors, and their direct versus indirect effects on oxidative？stress and intraneuronal accumulation.？We further illustrate that the molecule curcumin is a potential Aβ toxicity inhibitor as a β-sheet breaker by having？a high propensity to interact with certain Aβ residues without？binding to them. The comprehensive understanding gained from these current researches on the various toxicity mechanisms show promises in the provision of better therapeutics and treatment strategies in the near future.
References
[1]
Kirkitadze, M.D.; Bitan, G.; Teplow, D.B. Paradigm shifts in Alzheimer’s disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res 2002, 69, 567–577.
[2]
Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C.M.; Stefani, M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416, 507–511.
[3]
Verdier, Y.; Penke, B. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer’s disease. Curr. Protein Pept. Sci 2004, 5, 19–31.
[4]
Mutisya, E.M.; Bowling, A.C.; Beal, M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease. J. Neurochem 1994, 63, 2179–2184.
[5]
Huang, H.C.; Lin, C.J.; Liu, W.J.; Jiang, R.R.; Jiang, Z.F. Dual effects of curcumin on neuronal oxidative stress in the presence of Cu(II). Food Chem. Toxicol 2011, 49, 1578–1583.
[6]
Atamna, H.; Boyle, K. Amyloid-β peptide binds with heme to form a peroxidase: Relationship to the cytopathologies of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2006, 103, 3381–3386.
[7]
Wang, Q.; Walsh, D.M.; Rowan, M.J.; Selkoe, D.J.; Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci 2004, 24, 3370–3378.
[8]
Jang, H.; Zheng, J.; Lal, R.; Nussinov, R. New structures help the modeling of toxic amyloidβ ion channels. Trends Biochem. Sci 2008, 33, 91–100.
[9]
Jang, H.; Arce, F.T.; Ramachandran, S.; Capone, R.; Lal, R.; Nussinov, R. Structural convergence among diverse, toxic beta-sheet ion channels. J. Phys. Chem. B 2010, 114, 9445–9451.
[10]
Jang, H.; Arce, F.T.; Ramachandran, S.; Capone, R.; Azimova, R.; Kagan, B.L.; Nussinov, R.; Lal, R. Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer’s disease and Down syndrome. Proc. Natl. Acad. Sci. USA 2010, 107, 6538–6543.
[11]
Jang, H.; Arce, F.T.; Ramachandran, S.; Capone, R.; Lal, R.; Nussinov, R. β-Barrel Topology of Alzheimer’s β-Amyloid Ion Channels. J. Mol. Biol 2010, 404, 917–934.
Sepulveda, F.J.; Parodi, J.; Peoples, R.W.; Opazo, C.; Aguayo, L.G. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 2010, 5, doi:10.1371/journal.pone.0011820.
Lührs, T.; Ritter, C.; Adrian, M.; RiekLoher, D.; Bohrmann, B.; Dbeli, H.; Schubert, D.; Riek, R. 3D structure of Alzheimer’s amyloid-β (1–42) fibrils. Proc. Natl. Acad. Sci. USA 2005, 102, 17342–17347.
[16]
Takahashi, T.; Mihara, H. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Acc. Chem. Res 2008, 41, 1309–1318.
[17]
Kirkitadze, M.D.; Kowalska, A. Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer’s disease. Acta Biochim. Pol 2005, 52, 417–423.
[18]
Zhao, L.N.; Chiu, S.W.; Benoit, J.; Chew, L.Y.; Mu, Y. Amyloid β peptide aggregation in a mixed membrane bilayer: A molecule dynamic study. J. Phys. Chem. B 2011, 115, 12247–12256.
[19]
Zhao, L.N.; Chiu, S.W.; Benoit, J.; Chew, L.Y.; Mu, Y. The effect of curcumin on the stability of Aβ dimers. J. Phys. Chem. B 2012. (in Press).
[20]
Jang, S.; Shin, S. Amyloid β-peptide oligomerization in silico: Dimer and trimer. J. Phys. Chem. B 2006, 110, 1955–1958.
Barz, B.; Urbanc, B. Dimer formation enhances structural differences between amyloid β-protein (1–40) and (1–42): An explicit-solvent molecular dynamics study. PLoS One 2012, 7, doi:10.1371/journal.pone.0034345.
[23]
C？té, S.; Laghaei, R.; Derreumaux, P.; Mousseau, N. Distinct dimerization for various alloforms of the amyloid-beta protein: Aβ1–40, Aβ1–42, and Aβ1–40(D23N). J. Phys. Chem. B 2012, 116, 4043–4055.
[24]
Mitternacht, S.; Staneva, I.; H？rd, T.; Irb？ck, A. Monte carlo study of the formation and conformational properties of dimers of Aβ 42 variants. J. Mol. Biol 2011, 410, 357–367.
[25]
Williams, T.L.; Serpell, L.C. Membrane and surface interactions of Alzheimer’s Aβ peptide-insights into the mechanism of cytotoxicity. FEBS J 2011, 278, 3905–3917.
[26]
Zhao, J.; Wang, Q.M.; Liang, G.Z.; Zheng, J. Molecular dynamics simulations of low-ordered Alzheimer beta-amyloid oligomers from dimer to hexamer on self-assembled monolayers. Langmuir 2011, 27, 14876–14887.
[27]
Wang, Q.; Zhao, J.; Yu, X.; Zhao, C.; Li, L.; Zheng, J. Alzheimer Abeta(1–42) monomer adsorbed on the self-assembled monolayers. Langmuir 2010, 26, 12722–12732.
[28]
Tsai, H.H.; Lee, J.B.; Tseng, S.S.; Pan, X.A.; Shih, Y.C. Folding and membrane insertion of amyloid-beta (25–35) peptide and its mutants: Implications for aggregation and neurotoxicity. Protein 2010, 78, 1909–1925.
[29]
Maltseva, E.; Brezesinski, G. Adsorption of amyloid beta (1–40) peptide to phosphatidyl-ethanolamine monolayers. ChemPhysChem 2004, 5, 1185–1190.
[30]
Ionov, M.; Klajnert, B.; Gardikis, K.; Hatziantoniou, S.; Palecz, B.; Salakhutdinov, B.; Cladera, J.; Zamaraeva, M.; Demetzos, C.; Bryszewska, M. Effect of amyloid beta peptides A β1–28 and Aβ25–40 on model lipid membranes. J. Therm. Anal. Calorim 2010, 99, 741–747.
[31]
Sgourakis, N.G.; Yan, Y.; McCallum, S.A.; Wang, C.; Garcia, A.E. The Alzheimer’s peptides Aβ 40 and 42 adopt distinct conformations in water: A combined MD/NMR study. J. Mol. Biol 2007, 368, 1448–1457.
[32]
Krone, M.G.; Hua, L.; Soto, P.; Zhou, R.; Berne, B.J.; Shea, J.E. Role of water in mediating the assembly of Alzheimer amyloid Aβ 16–22 protofilaments. J. Am. Chem. Soc 2008, 130, 11066–11072.
[33]
Glabe, C.C. Amyloid accumulation and pathogensis of Alzheimer’s Disease: Significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem 2005, 28, 167–177.
[34]
Chiu, S.; Pandti, S.; Scott, H.L.; Jakobsson, E. An improved united atom force field for simulation of mixed lipid bilayers. J. Phys. Chem. B 2009, 113, 2748–2763.
[35]
Pandit, S.A.; Chiu, S.W.; Jakobsson, E.; Grama, A.; Scott, H.L. Cholesterol packing around lipids with saturated and unsaturated chains: A simulation study. Langmuir 2008, 24, 6858–6865.
[36]
Pandit, S.A.; Chiu, S.W.; Jakobsson, E.; Grama, A.; Scott, H.L. Cholesterol Surrogates: A comparison of cholesterol and 16:0 ceramide in POPC Bilayers. Biophys. J 2007, 92, 920–927.
Nosé, S. A molecular dynamics method for simulations in the canonical ensemble. Mol. Phys 1984, 55, 255–268.
[40]
Hoover, W.G. Canonical dynamics: Equilibrium phase space distributions. Phys. Rev. A 1985, 31, 1695–1697.
[41]
Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem 1997, 113, 1463–1472.
[42]
Miyashita, N.; Straub, J.E.; Thirumalai, D.; Sugita, Y. Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations. J. Am. Chem. Soc 2009, 131, 3438–3439.
[43]
Leoni, V.; Solomon, A.; Kivipelto, M. Links between ApoE brain cholesterol metabolism, tau and amyloid β-peptide in patients with cognitive impairment. Biochem. Soc. Trans 2010, 38, 1021–1025.
[44]
Okada, T.; Wakabayashi, M.; Ikeda, K.; Matsuzaki, K. Formation of toxic fibrils of Alzheimer’s amyloid beta-protein-(1–40) by monosialoganglioside GM1, a neuronal membrane component. J. Mol.Biol 2007, 371, 481–489.
[45]
Molander-Melin, M.; Blennow, K.; Bogdanovic, N.; Dellheden, B.; M？nsson, J.E.; Fredman, P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development: Increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem 2005, 92, 171–182.
[46]
Wakabayashi, M.; Matsuzaki, K. Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts. FEBS Lett 2009, 583, 2854–2858.
[47]
Kakio, A.; Nishimoto, S.I.; Kozotsumi, Y.; Matsuzaki, K. Formation of a membrane-active form of amyloid β-protein in raft-like model membranes. Biochem. Biophys. Res. Commun 2003, 303, 514–518.
[48]
Yahi, N.; Aulas, A.; Fantini, J. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer’s β amyloid peptide (Aβ1-40). PLoS One 2010, 5, doi:10.1371/journal.pone.0009079.
[49]
Yu, X.; Zheng, J. Cholesterol promotes the interaction of Alzheimer β-amyloid monomer with lipid bilayer. J. Mol. Biol 2011. (in Press).
[50]
Wakabayashi, M.; Okada, T.; Kozutsumi, Y.; Matsuzaki, K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun 2005, 328, 1019–1023.
[51]
Kakio, A.; ichi Nishimoto, S.; Yanagisawa, K.; Kozutsumi, Y.; Matsuzaki, K. Interactions of amyloid β-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid? Biochemistry 2002, 41, 7385–7390.
[52]
Abramov, A.Y.; Ionov, M.; Pavlov, E.; Duchen, M.R. Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: Implications for Alzheimer’s disease. Aging Cell 2011, 10, 595–603.
[53]
Fantini, J.; Yahi, N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: Common mechanisms in neurodegenerative diseases. Expert Rev. Mol. Med 2010, 12, doi:10.1017/S1462399410001602.
[54]
Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol 2000, 156, 15–20.
[55]
Wegiel, J.; Kuchna, I.; Nowicki, K.; Frackowiak, J.; Mazur-Kolecka, B.; Imaki, H.; Wegiel, J.; Mehta, P.D.; Silverman, W.P.; Reisberg, B.; et al. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol 2007, 113, 389–420.
[56]
Bayer, T.A.; Wirths, O. Intracellular accumulation of amyloid-beta—A predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front. Aging Neurosci 2010, 2, 1–9.
[57]
Cuello, A.C. Intracellular and extracellular Abeta, a tale of two neuropathologies. Brain Pathol 2005, 15, 66–71.
[58]
Nagele, R.G.; Dándrea, M.R.; Anderson, W.J.; Wang, H.Y. Intracellular accumulation of beta-amyloid (1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 2002, 110, 199–211.
[59]
Dándrea, M.R.; Nagele, R.G. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer’s disease pyramidal neurons. Curr. Pharm. Des 2006, 12, 677–684.
[60]
Fuentealba, R.A.; Liu, Q.; Zhang, J.; Kanekiyo, T.; Hu, X.; Lee, J.M.; LaDu, M.; Bu, G. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Aβ42 uptake and lysosomal trafficking. PLoS One 2010, 5, doi:10.1371/journal.pone.0011884.
[61]
Takuma, K.; Fang, F.; Zhang, W.; Yan, S.; Fukuzaki, E.; Du, H.; Sosunov, A.; McKhann, G.; Funatsu, Y.; Nakamichi, N.; et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction. Proc. Natl. Acad. Sci. USA 2009, 106, 20021–20026.
[62]
LaFerla1, F.M.; Green1, K.N.; Oddo, S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci 2007, 8, 499–509.
[63]
Lai, A.Y.; McLaurin, J. Mechanisms of amyloid-beta peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins. Int. J. Alzheimer’s Dis 2011, 2011, doi:10.4061/2011/548380.
[64]
Christensen, D.Z.; Schneider-Axmann, T.; Lucassen, P.J.; Bayer, T.A.; Wirths, O. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype. Acta Neuropathol 2010, 119, 555–566.
[65]
Pigino, G.; Morfini, G.; Atagi, Y.; Deshpande, A.; Yu, C.; Jungbauer, L.; LaDu, M.; Busciglio, J.; Brady, S. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc. Natl. Acad. Sci. USA 2009, 106, 5907–5912.
[66]
Christensen, D.Z.; Bayer, T.A.; Wirths, O. Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer’s disease. Neurobiol. Aging 2010, 31, 1153–1163.
[67]
Christensen, D.Z.; Kraus, S.L.; Flohr, A.; Cotel, M.C.; Wirths, O.; Bayer, T.A. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 2008, 116, 647–655.
[68]
Bayer, T.A.; Wirths, O. Review on the APP/PS1KI mouse model: Intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav 2008, 7, 6–11.
Arispe, N.; Rojas, E.; Pollard, H.B. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. USA 1993, 90, 567–571.
[73]
Wong, P.T.; Schauerte, J.A.; Wisser, K.C.; Ding, H.; Lee, E.L.; Steel, D.G.; Gafni, A. Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J. Mol. Biol 2009, 386, 81–96.
Lin, H.; Bhatia, R.; Lal, R. Amyloid beta protein forms ion channels: Implications for Alzheimer’s disease pathophysiology. FASEB J 2001, 15, 2433–2444.
[76]
Lin, H.; Zhu, Y.J.; Lal, R. Amyloid β protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 1999, 38, 11189–11196.
[77]
Kagan, B.L.; Hirakura, Y.; Azimov, R.; Azimova, R.; Lin, M.C. The channel hypothesis of Alzheimer’s disease: Current status. Peptides 2002, 23, 1311–1315.
[78]
Diaz, J.C.; Simakova, O.; Jacobson, K.A.; Arispe, N.; Pollard, H.B. Small molecule blockers of the Alzheimer Aβ calcium channel potently protect neurons from Aβ cytotoxicity. Proc. Natl. Acad. Sci USA 2009, 106, 3348–3353.
[79]
Felice, F.G.D.; Vieira, M.N.N.; Bomfim, T.R.; Decker, H.; Velasco, P.T.; Lambert, M.P.; Viola, K.L.; Zhao, W.Q.; Ferreira, S.T.; Klein, W.L. Protection of synapses against Alzheimer’s-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers. Neuroscience 2009, 106, 1971–1976.
[80]
Lacor, P.N.; Buniel, M.C.; Furlow, P.W.; Clemente, A.S.; Velasco, P.T.; Wood, M.; Viola, K.L.; Kleinaalina, W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J. Neurosci 2007, 27, 796–807.
Verges, D.K.; Restivo, J.L.; Goebel, W.D.; Holtzman, D.M.; Cirrito, J.R. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo. J. Neurosci 2011, 31, 11328–11337.
[92]
Bordji, K.; Becerril-Ortega, J.; Nicole, O.; Buisson, A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J. Neurosci 2010, 30, 15927–15942.
[93]
R？nicke, R.; Mikhaylova, M.; R？nicke, S.; Meinhardt, J.; Schr？der, U.H.; F？ndrich, M.; Reiser, G.; Kreutz, M.R.; Reymann, K.G. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging 2011, 32, 2219–2228.
[94]
Bicca, M.A.; Figueiredo, C.P.; Piermartiri, T.C.; Meotti, F.C.; Bouzon, Z.L.; Tasca, C.I.; Medeiros, R.; Calixto, J.B. The selective and competitive N-methyl-D-aspartate receptor antagonist, (？)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-β in mice. Neuroscience 2011, 192, 631–641.
[95]
Maglio, L.E.; Martins, V.R.; Izquierdo, I.; Ramirez, O.A. Role of cellular prion protein on LTP expression in aged mice. Brain Res 2006, 1097, 11–18.
[96]
Criado, J.R.; Sanchez-Alavez, M.; Conti, B.; Giacchino, J.L.; Wills, D.N.; Henriksen, S.J.; Race, R.; Manson, J.C.; Chesebro, B.; Oldstone, M.B. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol. Dis 2005, 19, 255–265.
[97]
Khosravani, H.; Zhang, Y.; Tsutsui, S.; Hameed, S.; Altier, C.; Hamid, J.; Chen, L.; Villemaire, M.; Ali, Z.; Jirik, F.R.; et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J. Cell Biol 2008, 181, 551–565.
[98]
Vassallo, N.; Herms, J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J. Neurochem 2003, 86, 538–544.
[99]
McLennan, N.F.; Brennan, P.M.; McNeill, A.; Davies, I.; Fotheringham, A.; Rennison, K.A.; Ritchie, D.; Brannan, F.; Head, M.W.; Ironside, J.W.; et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am. J. Pathol 2004, 165, 227–235.
[100]
Shyu, W.C.; Lin, S.Z.; Chiang, M.F.; Ding, D.C.; Li, K.W.; Chen, S.F.; Yang, H.I.; Li, H. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J. Neurosci 2005, 25, 8967–8977.
[101]
Santuccione, A.; Sytnyk, V.; Leshchyns’ka, I.; Schachner, M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J. Cell Biol 2005, 169, 341–354.
[102]
Laurén, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009, 457, 1128–1132.
[103]
Kessels, H.W.; Nguyen, L.N.; Nabavi, S.; Malinow, R. The prion protein as a receptor for amyloid-β. Nature 2010, 457, 1128–1132.
[104]
Calella, A.M.; Farinelli, M.; Nuvolone, M.; Mirante, O.; Moos, R.; Falsig, J.; Mansuy, I.M.; Aguzzi, A. Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med 2010, 2, 306–314.
[105]
Wang, H.Y.; Lee, D.H.S.; D’Andrea, M.R.; Peterson, P.A.; Shank, R.P.; Reitz, A.B. β-Amyloid(1-42) binds to α7 nicotinic acetylcholine receptor with high affinity: Implications for Alzheimer’s disease pathology. J. Biol. Chem 2000, 275, 5626–5632.
[106]
Pettit, D.L.; Shao, Z.; Yakel, J.L. β-amyloid 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci 2001, 21, RC120–RC125.
[107]
Liu, Q.S.; Kawai, H.; Berg, D.K. Beta-amyloid peptide blocks the response of alpha7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. USA 2001, 48, 4734–4739.
[108]
Dougherty, J.J.; Wu, J.; Nichols, R.A. β-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci 2003, 23, 6740–6747.
[109]
Hernandez, C.M.; Kayed, R.; Zheng, H.; Sweatt, J.D.; Dineley, K.T. Loss of α7 nicotinic receptors enhances β-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and Septohippocampal pathology in a mouse model of Alzheimer’s disease. J. Neurosci 2010, 30, 2442–2453.
[110]
Wang, H.Y.; Bakshi, K.; Shen, C.; Frankfurt, M.; Trocmé-Thibíerge, C.; Morain, P. S24795 limits β-amyloid-α7 nicotinic receptor interaction and reduces Alzheimer’s disease-like pathologies. Biol. Psychiatry 2010, 67, 522–530.
[111]
Lagostena, L.; Trocme-Thibierge, C.; Morain, P.; Cherubini, E. The partial α7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 2008, 54, 676–685.
[112]
Beracochea, D.; Boucard, A.; Trocme-Thibierge, C.; Morain, P. Improvement of contextual memory by S24795 in aged mice: Comparison with memantine. Psychopharmacology 2008, 196, 555–564.
[113]
Small, D.H.; Maksel, D.; Kerr, M.L.; Ng, J.; Hou, X.; Chu, C.; Mehrani, H.; Unabia, S.; Azari, M.F.; Loiacono, R.; et al. The beta-amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J. Neurochem 2007, 101, 1527–1538.
[114]
Knowles, J.K.; Rajadas, J.; Nguyen, T.V.V.; Yang, T.; LeMieux, M.C.; Griend, L.V.; Ishikawa, C.; Massa, S.M.; Wyss-Coray, T.; Longo, F.M. The p75 neurotrophin receptor promotes amyloid-β (1-42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci 2009, 29, 10627–10637.
[115]
Bengoechea, T.G.; Chen, Z.; O’Learya, D.A.; Masliahb, E.; Lee, K.F. p75 reduces β-amyloid-induced sympathetic innervation deficits in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. USA 2009, 106, 7870–7675.
[116]
Boland, K.; Manias, K.; Perlmutter, D.H. Specificity in recognition of amyloid-beta peptide by the serpin-enzyme complex receptor in hepatoma cells and neuronal cells. J. Biol. Chem 1995, 270, 28022–28028.
[117]
Joslin, G.; Griffin, G.L.; August, A.M.; Adams, S.; Fallon, R.J.; Senior, R.M.; Perlmutter, D.H. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide. J. Clin. Invest 1992, 90, 1150–1154.
[118]
Schmidt, A.M.; Sahagan, B.; Nelson, R.B.; Selmer, J.; Rothlein, R.; Bell, J.M. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr. Opin. Investig. Drugs 2009, 10, 672–680.
[119]
Baiguera, S.; Fioravanzo, L.; Grandi, C.; Liddo, R.D.; Parnigotto, P.P.; Folin, M. Involvement of the receptor for advanced glycation-end products (RAGE) in beta-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro. Int. J. Mol. Med 2009, 24, 9–15.
[120]
Prk, L.; Wng, G.; Zhou, P.; Zhou, J.; Pitstick, R.; Previtic, M.L.; Younkind, L.; Younkind, S.G.; Nostrndc, W.E.V.; Choe, S.; et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-β. Proc. Natl. Acad. Sci. USA 2011, 108, 5063–5068.
[121]
Silverstein, R.L.; Febbraio, M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal 2009, 2, 1–8.
[122]
Coraci, I.S.; Husemann, J.; Berman, J.W.; Hulette, C.; Dufour, J.H.; Campanella, G.K.; Luster, A.D.; Silverstein, S.C.; El-Khoury, J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol 2002, 160, 101–112.
[123]
Varadarajan, S.; Yatin, S.; Aksenova, M.; Butterfield, D.A. Review: Alzheimer’s amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol 2000, 130, 184–208.
[124]
Butterfield, D.A.; Reed, T.; Newman, S.F.; Sultana, R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic. Biol. Med 2007, 43, 658–677.
[125]
Jo, D.G.; Arumugam, T.V.; Woo, H.N.; Park, J.S.; Tang, S.C.; Mughal, M.; Hyun, D.H.; Park, J.H.; Choi, Y.H.; Gwon, A.R.; et al. Evidence that γ-secretase mediates oxidative stress-induced β-secretase expression in Alzheimer’s disease. Neurobiol. Aging 2010, 31, 917–925.
[126]
Zheng, L.; K？gedal, K.; Dehvari, N.; Benedikz, E.; Cowburn, R.; Marcusson, J.; Terman, A. Oxidative stress induces macroautophagy of amyloid β-protein and ensuing apoptosis. Free Radic. Biol. Med 2009, 46, 422–429.
[127]
Abdul, H.M.; Butterfield, D.A. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-l-carnitine and α-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: Implications for Alzheimer’s disease. Free Radic. Biol. Med 2007, 42, 371–384.
[128]
Naoi, M.; Maruyama, W.; Shamoto-Nagai, M.; Yi, H.; Akao, Y.; Tanaka, M. Oxidative stress in mitochondria: Decision to survive and death of neurons in neurodegenerative disorder. Mol. Neurobiol 2005, 31, 81–93.
[129]
Castegna, A.; Aksenov, M.; Aksenova, M.; Thongboonkerd, V.; Klein, J.B.; Pierce, W.M.; Booze, R.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med 2002, 33, 562–571.
[130]
Castegna, A.; Aksenov, M.; Thongboonkerd, V.; Klein, J.B.; Pierce, W.M.; Booze, R.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem 2002, 82, 1524–1532.
[131]
Sultana, R.; Perluigi, M.; Butterfield, D.A. Redox proteomics identification of oxidatively modified proteins in Alzheimer’s disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J. Chromatogr. B Anal. Technol. Biomed. Life Sci 2006, 833, 3–11.
[132]
Butterfield, D.A.; Boyd-Kimball, D. The critical role of methionine 35 in Alzheimer’s amyloid β- peptide (1-42)-induced oxidative stress and neurotoxicity. Biochimi. Biophys. Acta (BBA)-Protein Proteomics 2005, 1703, 149–156.
[133]
Butterfield, D.A.; Galvan, V.; Lange, M.B.; Tang, H.; Sowell, R.A.; Spilman, P.; Fombonne, J.; Gorostiza, O.; Zhang, J.; Sultana, R.; et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APP. Free Radic. Biol. Med 2010, 48, 136–144.
[134]
Muthaiyah, B.; Essa, M.M.; Chauhan, V.; Chauhan, A. Protective effects of walnut extract against amyloid beta peptide-induced cell death and oxidative stress in PC12 cells. Biomed. Life Sci 2011, 36, 2096–2103.
Tomaselli, S.; Esposito, V.; Vangone, P.; van Nuland, N.A.J.; Bonvin, A.M.J.J.; Guerrini, R.; Tancredi, T.; Temussi, P.A.; Picone, D. The α-to-β conformational transition of Alzheimer’s Aβ-(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of β conformation seeding. ChemBioChem 2006, 7, 257–267.
[137]
Hayat, S.; Helms, V. Towards understanding the early events in the conformational transition of amyloid beta peptides. Comput. Biophys. Syst. Biol. (CBSB08) 2008, 40, 227–230.
[138]
Xu, Y.; Shen, J.; Luo, X.; Zhu, W.; Chen, K.; Ma, J.; Jiang, H. Conformational transition of amyloid β-peptide. Proc. Natl. Acad. Sci. USA 2005, 102, 5403–5407.
[139]
Creighton, T.E. Protein Folding; W.H. Freeman & Company: New York, NY, USA, 1992.
[140]
Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–13383.
[141]
Zimm, H.; Bragg, J.K. Theory of the phase transition between helix and random coil in polypeptide chains. J. Chem. Phys 1959, 31, 526–535.
[142]
Lifson, S.; Roig, A. On the theory of helix-coil transition in polypeptides. J. Chem. Phys 1961, 34, 1963.
[143]
Kao, Y.M.; Jiang, T.F. Transition temperatures of the trapped ideal spinor Bose gas. Eur. Phys. J. D 2006, 40, 363–269.
[144]
Yakubovich, A.V.; Solov’yov, I.A.; Solov’yov, A.V.; Greiner, W. Ab initio theory of helix-coil phase transition. Eur. Phys. J. D 2008, 46, doi:10.1140/epjd/e2007-00328-9.
[145]
Solovyov, I.A.; Yakubovich, A.V.; Solovyov, A.V.; Greiner, W. α-helix ？ random coil phase transition: Analysis of ab initio theory predictions. Eur. Phys. J. D 2008, 46, 227–240.
[146]
Ding, F.; Borreguero, J.M.; Buldyrey, S.V.; Stanley, H.E.; Dokholyan, N.V. Mechanism for the alpha-helix to beta-hairpin transition. Proteins 2003, 53, 220–228.
[147]
Hong, L.; Lei, J. Statistical mechanical model for helix-sheet-coil transitions in homopolypeptides. Phys. Rev. E 2008, 78, 051904.
[148]
Yasar, F.; Demir, K. The study of helix-coil transition of polyalanine with single histogram method. Comput. Phys. Commun 2006, 175, 604–611.
[149]
Gibbs, H.; Dimarzio, E.A. Statistical mechanics of helix-coil transitions in biological macromolecules. J. Chem. Phys 1959, 30, 271–282.
[150]
Huang, K. Protein folding as a physical stochastic process. Biophys. Rev. Lett 2008, 3, 1–2.
[151]
Huang, K. Conditioned self-avoiding walk (csaw): Stochastic approach to protein folding. Biophys. Rev. Lett 2007, 139–154.
[152]
Leong, H.W.; Chew, L.Y.; Huang, K. Normal modes and phase transition of the protein chain based on the Hamiltonian formalism. Phys. Rev. E 2010, 82, doi:10.1103/PhysRevE.82.011915.
[153]
Goh, B.C.; Leong, H.W.; Qu, X.; Chew, L.Y. The mechanism of antiparallel β-sheet formation based on conditioned self-avoiding walk. Eur. Phys. J. E 2012, 35, doi:10.1140/epje/i2012-12027-8.
[154]
Jiang, P.; Li, W.F.; Shea, J.E.; Mu, Y. Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22–27. Biophys. J 2011, 100, 1550–1558.
[155]
Qin, X.R.; Abe, H.; Nakanishi, H. NMR and CD studies on the interaction of Alzheimer β-amyloid peptide (12-28) with β-cyclodextrin. Biochem. Biophys. Res. Commun 2002, 297, 1011–1015.
[156]
Camilleri, P.; Haskins, N.J.; Hewlett, D.R. β-Cyclodextrin interacts with the Alzheimer amyloid β-A4 peptide. FEBS Lett 1994, 341, 256–258.
[157]
Colombo, R.; Carotti, A.; Catto, M.; Racchi, M.; Lanni, C.; Verga, L.; Caccialanza, G.; Lorenzi, E.D. CE can identify small molecules that selectively target soluble oligomers of amyloid β protein and display antifibrillogenic activity. Electrophoresis 2009, 30, 1418–1429.
[158]
Cohen, A.D.; Ikonomovic, M.D.; Abrahamson, E.E.; Paljug, W.R.; DeKosky, S.T.; Lefterov, I.M.; Koldamova, R.P.; Shao, L.; Debnath, M.L.; Mason, N.S.; et al. Anti-amyloid effects of small molecule Aβ-binding agents in PS1/APP mice. Lett. Drug. Des. Discov 2009, 6, 437.
[159]
Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem 2005, 280, 5892–5901.
[160]
Inbar, P.; Bautista, M.R.; Takayama, S.A.; Yang, J. Assay to screen for molecules that associate with Alzheimer’s related beta-amyloid fibrils. Anal. Chem 2008, 80, 3502–3506.
[161]
Garcia-Alloza, M.; Borrelli, L.A.; Rozkalne, A.; Hyman, B.T.; Bacskai, B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem 2007, 102, 1095–1104.
[162]
Caesar, I.; Jonson, M.; Nilsson, K.P.R.; Thor, S.; Hammarstr？m, P. Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic drosophila. PLoS One 2012, 7, doi:10.1371/journal.pone.0031424.
[163]
Park, S.Y.; Kim, H.S.; Cho, E.K.; Kwon, B.Y.; Phark, S.; Hwang, K.W.; Sula, D. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol 2008, 46, 2881–2887.
[164]
Masuda, Y.; Fukuchi, M.; Yatagawa, T.; Tada, M.; Takeda, K.; Irie, K.; ichi Akagi, K.; Monobe, Y.; Imazawa, T.; Takegoshi, K. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. Bioorg. Med. Chem 2011, 19, 5967–5974.
[165]
Ellson, J.; Gansner, E.; Koutsofios, L.; North, S.; Woodhull, G.; Description, S.; Technologies, L. Graphviz-Open Source Graph Drawing Tools. In Lecture Notes in Computer Science; Springer-Verlag: Heidelberger/Berlin, Germany, 2001; pp. 483–484.
